Abcam

Abcam's reported carbon emissions

Abcam, a pharmaceutical preparation manufacturing company headquartered in Great Britain, reported total carbon emissions of approximately 5.3 million kg CO2e in 2024. This figure encompasses Scope 1, 2, and 3 emissions. For 2023, Abcam's total emissions were approximately 3.9 million kg CO2e, covering Scope 1 and 2. Scope 3 emissions data for 2023 were not fully disclosed. In 2022, Abcam's total emissions amounted to approximately 102.3 million kg CO2e, with Scope 1 emissions totalling about 1.2 million kg CO2e, Scope 2 emissions at approximately 3.4 million kg CO2e, and Scope 3 emissions reaching approximately 97.7 million kg CO2e. The company's total emissions for 2021 were approximately 87.9 million kg CO2e, comprising Scope 1 emissions of about 1.1 million kg CO2e, Scope 2 emissions of approximately 4.1 million kg CO2e, and Scope 3 emissions of roughly 82.6 million kg CO2e. In 2020, Abcam reported total emissions of approximately 55 million kg CO2e, with Scope 1 emissions at approximately 1.6 million kg CO2e, Scope 2 emissions at around 3.2 million kg CO2e, and Scope 3 emissions at approximately 4.8 million kg CO2e. Abcam's emissions data is cascaded from its corporate family. Abcam Limited is identified as the source organisation for CDP and RE100 initiatives, as well as performance data. For SBTi reduction targets, the data is cascaded from Danaher Corporation. While specific reduction targets and achievements are not detailed in the provided information, Abcam's reporting of Scope 1, 2, and 3 emissions indicates a commitment to tracking and managing its environmental impact within the pharmaceutical preparation manufacturing sector. The company has disclosed upstream Scope 3 categories, though some data points, such as purchased goods and services, were noted as missing in recent reporting years.